Raymond James Financial Inc. Makes New $15.99 Million Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

Raymond James Financial Inc. bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 102,061 shares of the company's stock, valued at approximately $15,989,000. Raymond James Financial Inc. owned approximately 0.35% of Krystal Biotech as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. US Bancorp DE lifted its position in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after acquiring an additional 121 shares during the last quarter. Envestnet Asset Management Inc. grew its position in Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock worth $1,822,000 after acquiring an additional 121 shares in the last quarter. Perigon Wealth Management LLC grew its position in Krystal Biotech by 1.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock worth $1,200,000 after acquiring an additional 123 shares in the last quarter. Finally, Xponance Inc. increased its stake in Krystal Biotech by 9.5% during the fourth quarter. Xponance Inc. now owns 1,785 shares of the company's stock worth $280,000 after acquiring an additional 155 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

KRYS has been the subject of a number of recent research reports. Citigroup lifted their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Chardan Capital lifted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. Jefferies Financial Group started coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, HC Wainwright reissued a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Krystal Biotech currently has an average rating of "Buy" and a consensus price target of $220.00.

Krystal Biotech Stock Down 0.6 %

KRYS stock traded down $1.06 during trading on Friday, hitting $168.06. The company had a trading volume of 171,300 shares, compared to its average volume of 295,591. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34. The company has a 50 day simple moving average of $176.37 and a 200-day simple moving average of $171.57. The firm has a market capitalization of $4.86 billion, a P/E ratio of 56.21 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company's quarterly revenue was up 116.4% compared to the same quarter last year. During the same period last year, the company posted $0.30 earnings per share. Sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).